Medgenics Moving In Record Time @ Seeking Alpha (MDGN)

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) is a clinical-stage biopharmaceutical company developing an innovative and proprietary platform technology - a biological "Biopump" - which allows patients to produce, within their bodies and on a long-term basis, their own natural human protein therapy for the treatment of a range of chronic diseases, such as anemia and hepatitis C.

At Seeking Alpha, contributor Ray Dirks wrote an article highlighting the Medgenics' recent news that "the FDA approved its filing to start clinical trials using its Biopump platform technology to treat anemia in kidney dialysis patients" in record time.

He writes, 

"As we've said in the past, EPODURE, one of MDGN's three proprietary Biopumps in development, looks to eliminate frequent, costly and inconvenient injections of erythropoietin (EPO). Amgen Inc. (AMGN) has owned this space for years and medicine is ready for a change.

Our FDA, known for its sluggishness and bad management, moved quickly to allow Medgenics to commence Phase IIb trials in the US, giving us their endorsement of a valuable technology that even the agency can't ignore. EPODURE works, and the FDA recognizes that our overburdened healthcare system can only benefit from the economics that Medgenics offers."

He continues,

"When MDGN announces the enrollment of its first subjects, we expect a leap in MDGN shares. The kidney dialysis market is more than 100,000 people start dialysis each year in the U.S., and last year there were 500,000 patients receiving dialysis, an estimated industry of $42.5 billion...

With more therapeutic areas targeted, a better platform technology, and progress achieved faster than we've seen with other biopharmaceuticals, do not miss out on this time to buy."

Read more at Seeking Alpha.